
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie demonstrates a positive financial outlook, with management projecting Neuroscience segment global sales to reach approximately $10.7 billion by 2025, an increase from previous expectations of $10.5 billion. The company has reported impressive global sales growth for key products, including Ubrelvy, Qulipta, and Botox Therapeutic, with figures indicating increases of around 32%, 64%, and 16%, respectively, year-over-year in Q3 2025. Additionally, the upward adjustments in estimates for Skyrizi and key Neuroscience products reflect AbbVie's robust prospects in both the immunology and aesthetics markets, underscoring the company's strategic position for future growth.
Bears say
AbbVie faces significant challenges due to anticipated erosion of Humira's market share from competing biosimilars beginning in 2025, which could severely impact revenue projections. The company's key products, Rinvoq and Skyrizi, are struggling to penetrate the market effectively, particularly in inflammatory bowel disease, raising concerns about achieving long-term growth targets. Additionally, broader macroeconomic pressures, such as competition in the aesthetics market and pipeline setbacks in its research and development phases, contribute to a negative outlook for AbbVie's financial performance.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares